Molecular testing for Fragile X Syndrome: lessons learned from 119,232 tests performed in a clinical laboratory

Genet Med. 2007 Jan;9(1):46-51. doi: 10.1097/gim.0b013e31802d833c.

Abstract

Purpose: To examine the data from over 119,000 Fragile X Syndrome tests and 307 prenatal tests to detect unsuspected findings and obtain clinical data when indicated to optimize genetic counseling.

Methods: A proprietary database containing 119,232 consecutive postnatal and 307 prenatal FXS tests performed between November 2, 1992 and June 1, 2006 was queried.

Results: The distribution of normal FMR1 alleles was a bimodal distribution with a major peak at 30 repeats and a minor peak at 21 repeats. Of 59,707 tests performed for males, 1.4% had a fully expanded and methylated FMR1 allele. Of 59,525 tests performed for females, 0.61% had an affected FMR1 allele, and 1.7% had a premutation FMR1 allele for a total carrier frequency of 1.3%. When fetuses inherited an expanded maternal allele, the risk of expansion to a full affected allele was 0%, 5%, 30% and 100% for allele sizes of <50, 50-75, 76-100 and >100 repeats, respectively.

Conclusions: These figures can be used for genetic counseling of patients presenting for carrier detection and prenatal diagnosis for Fragile X Syndrome.

MeSH terms

  • Adult
  • Child
  • Female
  • Fragile X Mental Retardation Protein / genetics*
  • Fragile X Syndrome / diagnosis*
  • Fragile X Syndrome / epidemiology
  • Fragile X Syndrome / genetics
  • Gene Frequency
  • Genetic Counseling*
  • Genetic Testing*
  • Heterozygote*
  • Humans
  • Laboratories
  • Male
  • Prenatal Diagnosis
  • Trinucleotide Repeat Expansion*

Substances

  • FMR1 protein, human
  • Fragile X Mental Retardation Protein